Sep 22, 2026
Immutep (NASDAQ: IMMP) Announces ADS Ratio Adjustment Effective September 28 to Meet Nasdaq Price Criteria
Immutep (NASDAQ: IMMP) will implement an ADS ratio adjustment effective September 28, 2026, reducing its ADS count from approximately 32.8 million to 1.64 million. This measure aims to ensure compliance with Nasdaq's $1.00 minimum bid price requirement before the October 26, 2026 deadline. The adjustment will not affect the company's ordinary share count, capital structure, cash reserves, or clinical development programs.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral
Sep 22, 2026
Immutep (IMMP) Announces 1-for-20 Reverse ADS Split to Meet Nasdaq Price Requirements
Immutep (IMMP) has announced a 1-for-20 reverse ADS split to meet Nasdaq's minimum bid-price requirement, effective September 28, 2026. This move comes as the company's ADS price lingered below $1 for an extended period, despite its Price-to-Sales ratio suggesting investor optimism for future growth. Immutep, a clinical-stage biotechnology firm, has a weak GF Score™ of 27/100, reflecting poor profitability and momentum but moderate financial strength.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish